Sub-Groups

• GDMT, Medicine (1903)
• GDMT, Pathology and Laboratory Medicine (1823)
• GDMT, Radiation Oncology (644)
• GDMT, Surgery (1962)

Types of Work

["2022"]

[[["Journal Articles",2466],["Meeting Abstracts",2106],["Book Sections",226],["Reviews",133],["Editorials",87],["Guidelines",38],["Correspondences",19],["Conference Papers",16],["Miscellaneous",12],["Research Letters",12],["Book Wholes",11]]]

[5126]

Popular keywords

• adult
• aged
• article
• cancer staging
• controlled study
• female
• human
• humans
• major clinical study
• middle aged

Recent Works

1. Phase 2 dose expansion of START-001: A phase 1/2 study of invikafusp alfa (STAR0602), a first-in-class, selective T cell receptor (TCR)-targeting, bifunctional antibody-fusion molecule, as monotherapy in patients with antigen-rich tumors resistant to anti-PD(L)-1

   Meeting Abstract

   Friedman, C. F.; Sullivan, R. J.; Tschernia, N.; Sonpavde, G. P.; Herrera, M.; He, K.; Bilusic, M.; Garralda, E.; Hernando-Calvo, A. H.; Silk, A. W.; more...
   Journal of Clinical Oncology (2025)

   Fulltext@MSK | Save
2. A phase 1, first-in-human study of CTIM-76, a claudin-6 (CLDN6)-directed bispecific antibody, in patients with recurrent ovarian cancer and other advanced solid tumors

   Meeting Abstract

   O'Cearbhaill, R. E.; Barve, M. A.; Darus, C.; Gabrail, N. Y.; Johannet, P.; Loh, J.; Lerose, M.; Andreas, K.; Ullmann, C. D.
   Journal of Clinical Oncology (2025)

   Fulltext@MSK | Save
3. ADAGIO: A phase IIb, open-label, single-arm, multicenter study assessing the efficacy and safety of adavosertib (AZD1775) as treatment for recurrent or persistent uterine serous carcinoma

   Journal Article

   Liu, J. F.; Colombo, N.; Oza, A. M.; Frenel, J. S.; Corr, B. R.; Rubinstein, M. M.; Nevadunsky, N. S.; Lheureux, S.; Gaba, L.; González Cortijo, L.; more...
   Journal of Clinical Oncology (2025)

   Fulltext@MSK | Save